Listen " Can Sirtex turn cancer into a chronic disease? "
Episode Synopsis
Big things sometimes come in small packages. For Sirtex Medical, the big thing comes in a really small package.
The Australian medical device company’s flagship product - the SIR-sphere - is made up of 30 to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and flow into the liver where they kill tumors from the inside.
In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson talks with Mangano about the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech companies to enter.
More episodes of the podcast DeviceTalks Podcast Network
J&J’s Schmid, Stanford’s Makower on helping MedTech find a higher gear for innovation and growth
21/11/2025
How Enovis is accelerating orthopedic recovery with bone stimulation and patient-centered innovation
18/11/2025
Noah Medical’s clear vision for pulmonary bronchoscopy; FOMO: The true costs of MedTech tariffs
14/11/2025
Reimagining GI with AI: Olympus’ Blended Intelligence Approach to Burnout Relief & Patient Safety
11/11/2025
Medtronic’s Kowal describes an exciting future and new applications for cardiac pacing devices
07/11/2025
How Abbott is rethinking heart failure management through smarter monitoring and long-term support
27/10/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.